Bevacizumab, a recombinant humanized monoclonal antibody against VEGF-A, whose action is to inhibit endothelial and tumor cell activation and proliferation, has been subject to Phase II clinical trials in recurrent or persistent endometrial cancer. This evidence concerns the gene VEGFA and neoplasm.